A detailed history of D. E. Shaw & Co., Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 334,781 shares of ALDX stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
334,781
Holding current value
$1.59 Million
% of portfolio
0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.19 - $6.32 $40,969 - $81,167
12,843 Added 3.99%
334,781 $1.8 Million
Q2 2024

Aug 14, 2024

SELL
$3.25 - $4.72 $733,531 - $1.07 Million
-225,702 Reduced 41.21%
321,938 $1.07 Million
Q1 2024

May 15, 2024

BUY
$2.77 - $4.22 $796,607 - $1.21 Million
287,584 Added 110.59%
547,640 $1.79 Million
Q4 2023

Feb 14, 2024

BUY
$1.47 - $6.06 $314,710 - $1.3 Million
214,089 Added 465.74%
260,056 $912,000
Q3 2023

Nov 14, 2023

SELL
$6.11 - $8.16 $183,379 - $244,906
-30,013 Reduced 39.5%
45,967 $307,000
Q2 2023

Aug 14, 2023

SELL
$7.11 - $11.89 $347,977 - $581,920
-48,942 Reduced 39.18%
75,980 $637,000
Q1 2023

May 15, 2023

SELL
$5.77 - $9.93 $1.29 Million - $2.21 Million
-222,947 Reduced 64.09%
124,922 $1.24 Million
Q4 2022

Feb 14, 2023

SELL
$5.08 - $7.09 $509,224 - $710,708
-100,241 Reduced 22.37%
347,869 $2.42 Million
Q3 2022

Nov 14, 2022

BUY
$3.8 - $7.74 $664,122 - $1.35 Million
174,769 Added 63.94%
448,110 $2.39 Million
Q2 2022

Aug 15, 2022

BUY
$2.43 - $4.85 $83,064 - $165,787
34,183 Added 14.29%
273,341 $1.09 Million
Q1 2022

May 16, 2022

BUY
$3.25 - $5.17 $659,522 - $1.05 Million
202,930 Added 560.15%
239,158 $1.06 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $9.63 $76,814 - $211,349
21,947 Added 153.68%
36,228 $145,000
Q3 2021

Nov 15, 2021

SELL
$7.94 - $11.31 $7,479 - $10,654
-942 Reduced 6.19%
14,281 $125,000
Q2 2021

Aug 16, 2021

SELL
$10.44 - $14.85 $30,578 - $43,495
-2,929 Reduced 16.14%
15,223 $172,000
Q1 2021

May 17, 2021

BUY
$6.53 - $14.42 $118,532 - $261,751
18,152 New
18,152 $216,000
Q4 2019

Feb 14, 2020

SELL
$4.73 - $7.98 $85,665 - $144,525
-18,111 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$4.41 - $6.12 $30,900 - $42,882
7,007 Added 63.1%
18,111 $95,000
Q2 2019

Aug 14, 2019

BUY
$6.0 - $9.0 $66,624 - $99,936
11,104 New
11,104 $67,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $278M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.